What is obe-cel and how does it treat leukaemia?

Obe-cel is a new therapy that genetically modifies a patient's cells to help their immune system recognize and attack leukaemia.

Who is eligible for the new leukaemia treatment approved by NHS?

The NHS has approved obe-cel for patients over 26 years old in England whose leukaemia has returned or not responded to other therapies.

How effective is the new leukaemia therapy?

Clinical trials showed that 77% of patients given obe-cel went into remission, with many remaining cancer-free for over three years.

Home / Health / Leukaemia Cure: NHS Approves Groundbreaking Cell Therapy

Leukaemia Cure: NHS Approves Groundbreaking Cell Therapy

25 Nov

•

Summary

A new one-time cell therapy, obe-cel, has been approved by NHS.
The treatment genetically modifies cells to target leukaemia effectively.
Clinical trials show high remission rates, with 77% achieving remission.

Leukaemia Cure: NHS Approves Groundbreaking Cell Therapy

A revolutionary treatment for leukaemia, known as obe-cel or Aucatzyl, has been granted NHS approval in England, offering new hope to over 150 patients annually. Developed by Autolus, a spin-out from University College London, this therapy involves a single course of intravenous doses designed to genetically modify a patient's cells.

The modified cells then enable the immune system to recognize and attack cancerous leukaemia cells. This innovative approach has shown remarkable efficacy in clinical trials, particularly for patients whose cancer has relapsed or resisted initial treatments. High remission rates and sustained remission have been observed, suggesting a potential functional cure.

Evidence from a trial involving 94 individuals revealed that 77% achieved remission, with a significant portion remaining cancer-free for over three years. This approval by the National Institute for Health and Care Excellence represents a substantial advancement in the fight against leukaemia, with similar treatments also available for younger patients.